# The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients

> **NCT02063607** · PHASE1 · COMPLETED · sponsor: **Nanogen Pharmaceutical Biotechnology Joint Stock Company** · enrollment: 60 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **BIOLOGICAL:** Peginterferon lambda

## Key facts

- **NCT ID:** NCT02063607
- **Lead sponsor:** Nanogen Pharmaceutical Biotechnology Joint Stock Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2015-02
- **Final completion:** 2016-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02063607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02063607, "The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02063607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*